LENZ Therapeutics Inc. Common Stock (LENZ)

About LENZ

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

152

Website

lenz-tx.com/

Fundamentals

1-day range

$4.69$5.13

Market cap

$156.62M

P/E (trailing)

—

P/E (forward)

-1.66

EPS (trailing)

$-3.59

Dividend yield

—

Beta

1.95

Avg. volume

847.6K

Dividend pay date

March 21, 2024

Forecasts

7 analyst ratings

LENZ Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• LENZ

  LENZ Therapeutics Inc. Common Stock

  $5.12

  ▲ 6.34%
  Market cap $156.62MP/E —
  $4.54$50.4
• TNYA

  Tenaya Therapeutics Inc. Common Stock

  $0.691

  ▼ 0.58%
  Market cap $158.19MP/E —
  $0.532$2.35
• HUMA

  Humacyte Inc. Common Stock

  $0.6538

  ▼ 5.66%
  Market cap $153.04MP/E —
  $0.5261$2.55
• CRBU

  Caribou Biosciences Inc. Common Stock

  $1.62

  ▼ 2.41%
  Market cap $148.77MP/E —
  $1.38$3.54
• VYGR

  Voyager Therapeutics Inc. Common Stock

  $3.54

  ▲ 2.17%
  Market cap $181.26MP/E —
  $2.94$5.55
• ARMP

  Armata Pharmaceuticals Inc. Common Stock

  $5.24

  ▼ 3.50%
  Market cap $185.39MP/E —
  $2.4$16.34
• ENGN

  enGene Therapeutics Inc. Common Stock

  $1.83

  ▼ 4.19%
  Market cap $118.57MP/E —
  $1.4$12.25

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

33.10M

Total value held

$293.01M

Institutional holders

139